Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 9Prostatic Neoplasms 8Neoplasms 5Lung Neoplasms 5Head and Neck Neoplasms 5Leukemia, Myeloid, Acute 4Hematologic Neoplasms 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Recurrence 2Pulmonary Disease, Chronic Obstructive 2Neoplasm Metastasis 2Lymphoma, Follicular 2Leukemia 2Colonic Neoplasms 2COVID-19 2Xerostomia 1Urologic Neoplasms 1Urologic Diseases 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Urinary Bladder Diseases 1Triple Negative Breast Neoplasms 1Teratoma 1Stroke 1Stomatitis 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Sarcoma 1

Interventions

padeliporfin 3palladium-bacteriopheophorbide 1enzalutamide 1darolutamide 1apalutamide 1Standard of Care 1Radiotherapy 1Prednisone 1Pluvicto 1Docetaxel 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Prostatic Diseases × Standard of Care × Clear all
NCT06496581 2024-12-20

Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

UNICANCER

Phase 3 Recruiting
500 enrolled
Genitourinary

Genital Diseases, Male, Prostatic Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡